Health care professionals

Empower stem cell transplantation for your AML patients

The CliniMACS® CD34 Reagent System is an FDA-approved method to deplete T cells for graft-versus-host disease (GVHD) prophylaxis. It is used for patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation in first complete remission.

See the data and learn about the CliniMACS CD34 Reagent System.

Product categories

Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.

Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.

Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.

Rx only

You have previously chosen International as your location.
What do you want to do?

Information for healthcare professionals

This content is intended for US healthcare professionals only. By clicking "yes" I am confirming that I am a healthcare professional.

If you are not a healthcare professional, please click here.